REDWOOD CITY, Calif., September 09, 2021 — Ashvattha Therapeutics, a clinical stage biotech company focused on novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in neurology, neuro-oncology, and ophthalmology, today announced that Jeffrey Cleland, Ph.D., Chairman, CEO and President will be presenting at the following upcoming virtual and in-person investor conferences:
- HC Wainwright 23rd Annual Global Investment Conference, Virtual (Sept 13-15)
- Cantor Fitzgerald Global Healthcare Conference, Virtual (Sept 27-30)
- BioFuture, Cure by Deerfield, 345 Park Avenue South, New York, NY (Oct 5-6)
Jeffrey Cleland, Ph.D., Chairman, CEO and President will present a corporate overview focused on Ashvattha’s clinical pipeline and corporate strategy.
“We recently announced positive interim data from our ongoing Phase 2 PRANA clinical study of our lead candidate OP-101 in severe COVID-19 patients, and will give an update on our additional clinical programs,” said Dr. Cleland. “OP-101 is the only clinical-stage therapeutic with the ability to shut down multiple pathways causing hyperinflammation. We look forward to speaking with investors and potential partners at these upcoming events, as we advance our novel pipeline of hydroxyl dendrimer therapeutics. Updates will include the plans for D-4517.2, a subcutaneous treatment for ocular neovascular disease, and OP-801, a novel radio-imaging agent, to be studied in combination with OP-101 in ALS patients.”
Ashvattha Therapeutics, a clinical-stage biopharmaceutical company, is developing novel therapeutics that target and alter specific cells in areas of diseased tissues. The Company’s targeted platform technology, hydroxyl dendrimers (HD), is exclusively licensed from Johns Hopkins University. HDs chemically conjugated to disease modifying drugs create novel proprietary HD therapeutics (HDTs). Ashvattha has initiated multiple programs with HDTs focused on neurology, ocular neovascular disease including neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME), neuro-oncology, and hyperinflammation in diseases such as COVID-19. For more information, visit: www.avttx.com.